RecruitingGout
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Eligible age
18–90 yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Sponsor: Massachusetts General Hospital
You may not qualify if…
- ✕ Candidates who meet any of the following criteria will be excluded from the study:
- ✕ 1. Diagnosis of CKD Stage 3B or worse (eGFR \< 45 mL/min/ 1.73 m2) at screening
- ✕ 2. More than one subcutaneous tophus on clinical examination at screening
- ✕ 3. Two or more episodes of renal colic in the past 5 years
- ✕ 4. Unable to provide informed consent.
- ✕ 5. AST/ALT \> 3 × upper limit of normal (ULN) (within 6 months of entry).
- ✕ 6. Pregnancy, planning pregnancy, or breastfeeding.
- ✕ 7. Patients who have been treated with thiopurines (mercaptopurine (PURINETHOL®), azathioprine (IMURAN®), or thioguanine) in the past 12 months or currently being treated with thiopurines are not eligible for the study. Usage of the thiopurines (azathioprine and mercaptopurine) with allopurinol has been shown to cause a significant drug-drug interaction.
Where it's recruiting
Alabama
South Birmingham
California
Santa Monica
Massachusetts
Boston
New York
New York
West Virginia
Morgantown
Source: ClinicalTrials.gov · NCT04875702 · last updated 2025-09-25